Alkermes

Alkermes is a biopharmaceutical company that applies neuroscience expertise to the development and commercialisation of medicines for people living with complex, difficult-to-treat psychiatric and neurological disorders. Its therapeutic focus spans addiction, serious mental illness and sleep disorders - conditions that the company notes have traditionally been overlooked or stigmatized.

The business combines two lines of work: a portfolio of marketed medicines for psychiatric and neurological disorders, and a pipeline of investigational new medicine candidates. These are supported by an integrated research strategy, clinical development capabilities and a specialized commercial infrastructure, with patient-inspired science described as the starting point for its research.

The company states that collaboration sits at the core of how it operates, and that its people - along with their empathy for patients, families and caregivers - are its greatest strength. Its stated core values guide its culture, which it describes as one that values every person and respects each voice, and it reports being recognized as an employer of choice in the biotech industry. Alkermes works with urgency to develop new treatment options in its chosen fields. Further information is available at https://alkermes.com/.